Japan’s biomarker and companion diagnostics (CDx) landscape is moving quickly. As regulatory frameworks mature and CDx co-development gains stronger institutional support, we’re seeing real momentum in precision oncology.
At the same time, familiar challenges remain: complex reimbursement pathways, gaps in implementation infrastructure, and ongoing misalignment between global and Japan-specific development and approval timelines.
That’s exactly why the World Clinical Biomarkers & CDx Summit Japan was created. It’s a focused forum designed to tackle these issues directly and practically. The agenda spans the entire biomarker-led drug development lifecycle from early clinical strategy and CDx co-development through regulatory approval, launch, reimbursement, and clinical adoption.
Across the two days, more than 80 senior leaders from biopharma, diagnostics, government, and healthcare systems come together to share perspectives and work toward greater alignment.
Whether you’re part of a global organization expanding into Japan or a domestic team looking to scale your impact, the summit is designed to provide clear regulatory insight, honest discussion around market access realities, and meaningful partnership opportunities. The goal is to help advance precision oncology in a way that aligns with Japan’s healthcare ecosystem.
Key areas of focus will be:
- Harmonizing global and Japan-specific CDx co-development strategies
- Regulatory pathways and approval considerations in Japan
- Reimbursement frameworks and market access challenges
- CDx implementation and infrastructure readiness
- Driving adoption of precision oncology in clinical practice
- Cross-sector collaboration between industry, regulators, and healthcare systems
About Hanson Wade Group - World Clinical Biomarkers & CDx Summit Japan
Harmonize Domestic & Global CDx Co-Development, Approval & Reimbursement Towards Accessible & Affordable Precision Oncology in Japan
Japan’s biomarker and companion diagnostics environment is undergoing significant transformation as regulatory frameworks mature and co-development approaches gain broader institutional backing. While this momentum is opening new pathways for innovation, it also exposes hurdles such as complex reimbursement mechanisms, gaps in CDx implementation infrastructure, and misalignment between global and Japan-specific development timelines.
The World Clinical Biomarkers & CDx Summit Japan stands alone as the only event built specifically to address these challenges. Covering every stage of biomarker-led drug development, from early clinical strategy through CDx launch and adoption, the summit unites 80+ senior decision-makers from biopharma, diagnostics, government bodies, and healthcare systems to catalyze collaboration and advance precision medicine.
For international companies establishing a presence in Japan and local organizations seeking to expand their impact, this summit delivers the strategic insight, network, and partnerships essential to navigating Japan’s complex precision medicine landscape.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.